NT5E and colorectal cancer: The combination of AB680, a potent CD73 selective inhibitor, and palbociclib can overcome the adverse reaction of the cyclin-dependent kinase 4/6 inhibitor palbociclib to induce increased expression of PD-L1 in tumors and significantly improve the antitumor efficacy of animal models of colorectal cancer (45).